|
US7514090B2
|
|
Monocyte locomotion inhibitory factor
|
|
US2005019743A1
|
|
Compounds and methods for improving platelet recovery and function
|
|
WO2004105837A2
|
|
Compounds and methods for improving platelet recovery and function
|
|
AU2003304386A1
|
|
Methods for treating and preventing apoptosis-related diseases using rna interfering agents
|
|
AU2003300781A8
|
|
Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
|
|
WO2004007530A2
|
|
Modified proteins stabilized in a desired conformation and methods for producing same
|
|
AU2003253735A8
|
|
Vacuolins
|
|
EP1390062A2
|
|
Modulators of elastase inhibitor secretion
|
|
US6689267B2
|
|
Multi-plate electrophoresis system having non-mechanical buffer circulation
|
|
US2003064380A1
|
|
Anergy-regulated molecules
|
|
WO0218583A2
|
|
Modified polypeptides stabilized in a desired conformation and methods for producing same
|
|
AU7537801A
|
|
Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
|
|
EP1714661A2
|
|
Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
|
|
WO0189564A2
|
|
Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
|
|
AU5945501A
|
|
Colloid compositions for solid phase biomolecular analytical, preparative and identification systems
|
|
AU3308001A
|
|
Modulation of tolerance by altering nfat signalling
|
|
AU4729199A
|
|
Monocyte locomotion inhibitory factor
|
|
WO9940930A1
|
|
Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
|
|
WO9910534A1
|
|
Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof
|
|
CA2298867A1
|
|
Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis
|
